<DOC>
	<DOCNO>NCT02815670</DOCNO>
	<brief_summary>The trial objective demonstrate safety idarucizumab , assess occurence patient drug relate adverse event ( include immune reaction ) all-cause mortality paediatric venous thromboembolism patient treat dabigatran ongoing clinical trial require emergency surgery/urgent procedure patient life-threatening uncontrolled bleeding require urgent intervention , rapid reversal anticoalugant effect dabigatran need .</brief_summary>
	<brief_title>Reversal Dabigatran Anticoagulant Effect With Idarucizumab</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Patients take dabigatran etexilate paediatric trial 1160.106 1160.108 eligible trial meet follow criterion : Group A : Overt bleed judge treat physician require reversal agent . Currently take dabigatran etexilate context clinical trial dabigatran etexilate ( 1160.106 1160.108 ) . Male female patient 0 less 18 year age time inform consent/assent participation trial 1160.106 trial 1160.108 . Female patient childbearing potential ( define experienced menarche ) must follow contraception requirement accord dabigatran trial 1160.106 trial 1160.108 enrol . Written inform consent provide patient ( and/or patient 's legally accepted representative ) assent provide patient ( applicable ) time inform consent signature accordance Good Clinical Practice ( GCP ) local legislation prior admission trial . If child unable give assent time emergency , assent , applicable obtain soon feasible . Group B : A condition require emergency surgery invasive procedure adequate haemostasis require . Emergency define need surgery intervention within follow 8 hour . Currently take dabigatran etexilate context clinical trial dabigatran etexilate ( 1160.106 1160.108 ) . Male female patient 0 less 18 year age time inform consent/assent participation trial 1160.106 trial 1160.108 . Female patient childbearing potential ( define experienced menarche ) must follow contraception requirement accord dabigatran trial 1160.106 trial 1160.108 enrol . Written inform consent provide patient ( and/or patient 's legally accepted representative ) assent provide patient ( applicable ) time inform consent signature accordance GCP local legislation prior admission trial . If child unable give assent time emergency , assent , applicable obtain soon feasible . Exclusion criterion : Group A : Patients minor bleeding ( e.g . epistaxis , haematuria ) manage standard supportive care . Patients clinical sign bleed . Patients body weight &lt; 2.5 kg Contraindications trial medication include know hypersensitivity drug excipients ; i.e . patient hereditary fructose intolerance may react sorbitol . Female patient pregnant , nursing , plan become pregnant trial . Group B : A surgery procedure elective risk uncontrolled unmanageable bleeding low . Patients body weight &lt; 2.5 kg Contraindications trial medication include know hypersensitivity drug excipients ; i.e . patient hereditary fructose intolerance may react sorbitol . Female patient pregnant , nursing , plan become pregnant trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>